189 related articles for article (PubMed ID: 21222171)
1. Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?
Hoffman RM; Roberts RG; Barry MJ
J Gen Intern Med; 2011 Jul; 26(7):798-801. PubMed ID: 21222171
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer chemoprevention with 5α-reductase inhibitors.
Nepple KG; Andriole GL
Urol Oncol; 2012 Sep; 30(5):553-4. PubMed ID: 23193568
[No Abstract] [Full Text] [Related]
3. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention using dutasteride: the REDUCE trial.
Gomella LG
Curr Opin Urol; 2005 Jan; 15(1):29-32. PubMed ID: 15586026
[TBL] [Abstract][Full Text] [Related]
5. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.
Wilt TJ; Macdonald R; Hagerty K; Schellhammer P; Tacklind J; Somerfield MR; Kramer BS
BJU Int; 2010 Nov; 106(10):1444-51. PubMed ID: 20977593
[TBL] [Abstract][Full Text] [Related]
6. 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
Hamilton RJ; Freedland SJ
BMC Med; 2011 Sep; 9():105. PubMed ID: 21920036
[TBL] [Abstract][Full Text] [Related]
7. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.
Pinsky PF; Black A; Grubb R; Crawford ED; Andriole G; Thompson I; Parnes H
Cancer; 2013 Feb; 119(3):593-601. PubMed ID: 22893105
[TBL] [Abstract][Full Text] [Related]
8. Evolving role of 5-alpha reductase inhibitors in chemoprevention.
White WM; Kim ED
Nat Rev Clin Oncol; 2010 Sep; 7(9):487-8. PubMed ID: 20798697
[No Abstract] [Full Text] [Related]
9. Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS; Fleshner NE; Thompson IM
Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
[TBL] [Abstract][Full Text] [Related]
10. 5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?
Al Edwan G; Fleshner N
Curr Urol Rep; 2013 Jun; 14(3):223-6. PubMed ID: 23579402
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride: novel milestones in prostate cancer chemoprevention.
Rove KO; Crawford ED
Drugs Today (Barc); 2011 Feb; 47(2):135-44. PubMed ID: 21431101
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of prostate cancer.
Vemana G; Hamilton RJ; Andriole GL; Freedland SJ
Annu Rev Med; 2014; 65():111-23. PubMed ID: 24188663
[TBL] [Abstract][Full Text] [Related]
14. Dutasteride for the treatment of prostate-related conditions.
Slater S; Dumas C; Bubley G
Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
[TBL] [Abstract][Full Text] [Related]
15. Decision analysis of dutasteride use for patients with negative prostate biopsy.
Vickers AJ; Sjoberg DD
Urology; 2015 Feb; 85(2):337-41. PubMed ID: 25623680
[TBL] [Abstract][Full Text] [Related]
16. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
17. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
18. [Chemoprevention of prostate cancer].
Djavan B; Thompson I; Michel MS; Waldert M; Seitz C
Urologe A; 2004 May; 43(5):557-61. PubMed ID: 15042290
[TBL] [Abstract][Full Text] [Related]
19. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
